Loading…
← CockpitCompetitor Analysis › 600129.SS Chongqing Taiji Industry (Group) Co., Ltd. Class AOpen in the cockpit ↗

Chongqing Taiji Industry (Group) Co., Ltd. Class A600129.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.

≈ A Chinese TCM OTC and distribution conglomerateMomentum weak 36
Mkt cap
$982M
US dollars, full cap
Free float
60%
of shares outstanding
$/day
$14.9M
20-day average traded
Fwd P/E
69.8×
forward earnings
ROIC−WACC
-1.0 pp
WACC 5.2%
Hurdle
n/a
no reverse DCF
Next earnings
128 days
26 Mar 2027
Close · CNYCN¥11.97
1D-1.2%
1W-6.2%
1M-11.4%
3M-27.9%
6M-19.8%
YTD-33.7%
1Y-42.4%
ATR %3.2%
52w lowhigh42.8% off high

What Chongqing Taiji Industry (Group) does

Chongqing pharma and distribution group known for its Huoxiang Zhengqi traditional digestive-remedy liquid.

Pharmaceutical distribution adds large sales volume at thin margins, while the branded remedy and other over-the-counter products sold through pharmacies carry most of the profit. The distribution arm supplies drugs and medical products to hospitals and pharmacies in the Chongqing region.

In one line: A Chinese TCM OTC and distribution conglomerate.

Products and services

  • Huoxiang Zhengqi digestive remedy
  • Pharmaceutical distribution
  • Other TCM products

Customers

  • Retail pharmacies
  • Hospitals

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • OTC and distribution

What could go right

  • OTC digestive-remedy demand

What could go wrong

  • High debt load
  • OTC price competition

Moat: narrow (brand, distribution). Long-established OTC brand plus a regional pharma distribution network.

Headquarters: Chongqing, China · Employees: 10,864

Named competitors

Chongqing Taiji Industry (Group) at a glance

Size Chongqing Taiji Industry (Group) (600129.SS) is a China Health Care company (Pharmaceuticals: Major) with a market value of $982M, the 2187th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥11.97 on 18 Nov 2026.

Performance Over six months the shares fell 19.8%, against -10.6% for the median peer and -20.0% for the China market (cap-weighted) — 8th lowest of 21 in its peer set.

Growth Revenue fell 4.5% over the last twelve months (peer median +9.8%); the operating margin is 1.5% (peer median 12.6%).

Valuation It trades at 69.8× forward earnings against a peer median of 19.8× (most expensive of 14).

Capital Return on invested capital runs 1.0 points below its cost of capital (5.2% WACC).

Next results Next results expected around 26 Mar 2027 (exchange calendar; dates can move).

Relative performance

8010012021 May 202621 Aug 202618 Nov 2026Peer median 92600129.SS 82
Six months, rebased to 100: Chongqing Taiji Industry (Group) against the median of its 20 peers (local-currency closes).

Chongqing Taiji Industry (Group) financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥9.59BCN¥10.4BCN¥12.3BCN¥15.4BCN¥14.0B
Revenue growth—-15%-20%+10%—
Gross profitCN¥3.03BCN¥2.76BCN¥4.64BCN¥7.14BCN¥6.00B
EBITDAn/aCN¥812MCN¥889MCN¥1.62BCN¥1.15B
Net income-CN¥19.6MCN¥121MCN¥26.7MCN¥822MCN¥354M
Free cash flow-CN¥215MCN¥64.1M-CN¥1.46B-CN¥160MCN¥1.26B
Capital expenditureCN¥400MCN¥523MCN¥832MCN¥836MCN¥532M
Total debtCN¥6.07BCN¥6.44BCN¥5.62BCN¥4.86BCN¥5.02B

Quarterly statements and history in the cockpit →

Chongqing Taiji Industry (Group) competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-20%0%+20%688382SPTXAARTIPHARMPGHL600557456568871060511668809168875930029448872005300702STAR603538002437600422600129.SS6-month return →1-month return →
Up and to the right = strong over both horizons. Chongqing Taiji Industry (Group) is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%20×40×60×PGHL60055745656887106051163002944887000650300702STAR603538300497600129.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Chongqing Taiji Industry (Group) is the large dot.

Chongqing Taiji Industry (Group) competitors and peer comparison

Head to head with its named competitors (600129.SS vs 600750.SS vs 000538.SZ vs 000999.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Chongqing Taiji Industry (Group) 600129.SS$982M-20%-4%2%69.8×n/a
China Resources Jiangzhong Pharmaceutical 600750.SS$2.27B+4%-10%24%16.5×-1.9%
Yunnan Baiyao 000538.SZ$15.0B+11%+5%11%18.3×-0.2%
China Resources Sanjiu Medical & Pharmaceutical 000999.SZ$6.59B+6%+4%14%13.2×-6.2%

How Chongqing Taiji Industry (Group) compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Chongqing Taiji Industry (Group) against its 20 peers (data as of 18 Nov 2026)
Measure600129.SSPeer medianRank in peer set
1-month return-11.4%-6.5%6th lowest of 21
6-month return-19.8%-10.6%8th lowest of 21
Distance from 52-week high-42.8%-33.9%9th lowest of 21
Revenue growth (TTM)-4.5%+9.8%6th lowest of 19
Operating margin1.5%12.6%4th lowest of 19
Forward P/E69.8×19.8×most expensive of 14
ROIC minus cost of capital-1.0 pp-0.4 pp9th lowest of 19

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Chongqing Taiji Industry (Group) 600129.SSChina$982M-20%-4%2%69.8×n/an/a
InventisBio 688382.SSChina$982M-47%-61%-563%n/a6.5%-60.6%
Seaport Therapeutics SPTXUnited States$980M+16%n/an/an/an/an/a
Aarti Pharmalabs AARTIPHARM.NSIndia$984M+44%+13%18%n/an/an/a
Procter & Gamble Health PGHL.NSIndia$979M+3%+13%31%24.5×5.6%+9.3%
Jiangsu Kanion Pharmaceutical 600557.SSChina$989M-9%+8%7%19.8×2.3%+1.8%
Nxera Pharma 4565.TJapan$974M+46%+24%14%25.8×17.7%+27.3%
Shanghai InnoStar Bio-tech 688710.SSChina$1,000M+17%+24%6%59.3×12.7%+19.4%
Aurisco Pharmaceutical 605116.SSChina$1.00B-23%+3%25%13.6×-2.0%+18.7%
Shanghai Yizhong Pharmaceutical 688091.SSChina$1.00B-49%+32%14%n/an/an/a
BeBetter Med 688759.SSChina$960M-58%n/an/an/an/an/a
China Resources Boya Bio-pharmaceutical 300294.SZChina$959M-21%-27%-19%21.4×n/an/a
SAWAI 4887.TJapan$1.01B-18%+2%9%12.0×n/an/a
Renhe Pharmacy 000650.SZChina$1.01B-12%-7%14%16.9×-10.7%-7.0%
SSY 2005.HKHong Kong$948M+8%-4%12%12.5×2.3%-0.5%
Zhejiang Tianyu Pharmaceutical 300702.SZChina$1.02B+1%+27%4%21.4×4.3%+3.5%
Strides Pharma Science STAR.NSIndia$946M-17%+11%14%15.9×17.6%+7.8%
Ningbo Menovo Pharmaceutical 603538.SSChina$945M-48%+19%9%42.3×11.6%+4.9%
Jiangxi Fushine Pharmaceutical 300497.SZChina$1.02B-23%+103%24%9.9×7.5%-4.5%
Harbin Gloria Pharmaceuticals 002437.SZChina$941M-9%-16%13%n/a7.7%-6.9%
KPC Pharmaceuticals 600422.SSChina$940M-6%-41%-10%n/an/an/a

Questions

Who are Chongqing Taiji Industry (Group)'s main competitors?
Named competitors: China Resources Jiangzhong Pharmaceutical (600750.SS), Yunnan Baiyao (000538.SZ), China Resources Sanjiu (000999.SZ). The cockpit's measured peer set (industry) also includes InventisBio (688382.SS), Seaport Therapeutics (SPTX), Aarti Pharmalabs (AARTIPHARM.NS), Procter & Gamble Health (PGHL.NS), Jiangsu Kanion Pharmaceutical (600557.SS), Nxera Pharma (4565.T).
Is Chongqing Taiji Industry (Group) expensive compared with its peers?
On forward p/e it trades at 69.8× against a peer median of 19.8×, most expensive of 14 in its peer set.
How has Chongqing Taiji Industry (Group) stock performed?
Over six months to 18 Nov 2026 the shares returned -19.8% against -10.6% for the median peer; over one year -42.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.